Literature DB >> 33099809

SIGLEC1 (CD169) as a potential diagnostical screening marker for monogenic interferonopathies.

Banu Orak1,2, Gonza Ngoumou1,2, Frédéric Ebstein3, Barbara Zieba3, Carl Christoph Goetzke1,4,5, Ellen Knierim2,6, Angela M Kaindl2,6,7, Axel Panzer8, Manuela Theophil8, Monika Berns9, Elke Krüger3, Christian Meisel10, Nadine Unterwalder10, Tilmann Kallinich1,2,4,5.   

Abstract

Entities:  

Year:  2020        PMID： 33099809     DOI： 10.1111/pai.13400

Source DB:  PubMed          Journal:  Pediatr Allergy Immunol        ISSN： 0905-6157            Impact factor:   6.377


× No keyword cloud information.
  5 in total

1.  SIGLEC1 (CD169): a marker of active neuroinflammation in the brain but not in the blood of multiple sclerosis patients.

Authors:  Lennard Ostendorf; Philipp Dittert; Robert Biesen; Ankelien Duchow; Victoria Stiglbauer; Klemens Ruprecht; Judith Bellmann-Strobl; Dominik Seelow; Werner Stenzel; Raluca A Niesner; Anja E Hauser; Friedemann Paul; Helena Radbruch
Journal:  Sci Rep       Date:  2021-05-13       Impact factor: 4.379

2.  CD169/SIGLEC1 is expressed on circulating monocytes in COVID-19 and expression levels are associated with disease severity.

Authors:  Jan-Moritz Doehn; Christoph Tabeling; Robert Biesen; Jacopo Saccomanno; Elena Madlung; Eva Pappe; Frieder Gabriel; Florian Kurth; Christian Meisel; Victor M Corman; Leif G Hanitsch; Sascha Treskatsch; Kathrin Heim; Miriam S Stegemann; Christoph Ruwwe-Glösenkamp; Holger C Müller-Redetzky; Alexander Uhrig; Rajan Somasundaram; Claudia Spies; Horst von Bernuth; Jörg Hofmann; Christian Drosten; Norbert Suttorp; Martin Witzenrath; Leif E Sander; Ralf-Harto Hübner
Journal:  Infection       Date:  2021-04-06       Impact factor: 3.553

3.  SIGLEC1 enables straightforward assessment of type I interferon activity in idiopathic inflammatory myopathies.

Authors:  Manuel Graf; Sae Lim von Stuckrad; Akinori Uruha; Jens Klotsche; Lydia Zorn-Pauly; Nadine Unterwalder; Thomas Buttgereit; Martin Krusche; Christian Meisel; Gerd R Burmester; Falk Hiepe; Robert Biesen; Tilmann Kallinich; Werner Stenzel; Udo Schneider; Thomas Rose
Journal:  RMD Open       Date:  2022-02

4.  SARS-CoV-2 T Cell Response in Severe and Fatal COVID-19 in Primary Antibody Deficiency Patients Without Specific Humoral Immunity.

Authors:  Sophie Steiner; Tatjana Schwarz; Victor M Corman; Laura Gebert; Malte C Kleinschmidt; Alexandra Wald; Sven Gläser; Jan M Kruse; Daniel Zickler; Alexander Peric; Christian Meisel; Tim Meyer; Olga L Staudacher; Kirsten Wittke; Claudia Kedor; Sandra Bauer; Nabeel Al Besher; Ulrich Kalus; Axel Pruß; Christian Drosten; Hans-Dieter Volk; Carmen Scheibenbogen; Leif G Hanitsch
Journal:  Front Immunol       Date:  2022-03-10       Impact factor: 7.561

Review 5.  Myeloid CD169/Siglec1: An immunoregulatory biomarker in viral disease.

Authors:  Silva Herzog; Paraskevi C Fragkou; Borros M Arneth; Samr Mkhlof; Chrysanthi Skevaki
Journal:  Front Med (Lausanne)       Date:  2022-09-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.